NASDAQ:RGLS - Regulus Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 386.62 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.41
▲ +0.02 (5.12%)

This chart shows the closing price for RGLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Regulus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGLS

Analyst Price Target is $2.00
▲ +386.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Regulus Therapeutics in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 386.62% upside from the last price of $0.41.

This chart shows the closing price for RGLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Regulus Therapeutics. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/2/2021Cantor FitzgeraldInitiated CoverageOverweight$2.00Medium
8/11/2021HC WainwrightReiterated RatingBuyHigh
5/14/2021HC WainwrightBoost Price TargetPositive ➝ Buy$1.50 ➝ $2.00High
9/1/2020HC WainwrightReiterated RatingBuyMedium
7/24/2020WedbushReiterated RatingHold$1.00Low
7/23/2020HC WainwrightReiterated RatingBuyHigh
6/11/2020WedbushReiterated RatingHold$1.00High
5/18/2020HC WainwrightReiterated RatingBuy$1.50Medium
5/15/2020Needham & Company LLCInitiated CoverageHoldMedium
5/4/2020HC WainwrightReiterated RatingBuy$2.00 ➝ $1.50High
3/17/2020WedbushReiterated RatingHold$1.00Low
2/13/2020WedbushReiterated RatingHold$1.00Medium
1/28/2020WedbushReiterated RatingHold$1.00Low
12/16/2019WedbushReiterated RatingHold$1.00High
11/14/2019WedbushReiterated RatingHold$1.00High
10/18/2019WedbushSet Price TargetHold$1.00High
9/6/2019HC WainwrightInitiated CoverageBuy$2.00High
8/13/2019Needham & Company LLCReiterated RatingHoldHigh
5/16/2019WedbushReiterated RatingHold$1.00Low
5/8/2019WedbushSet Price TargetHold$2.00 ➝ $1.00High
4/9/2019WedbushReiterated RatingHold$2.00Low
3/26/2019WedbushSet Price TargetHold$2.00High
3/19/2019Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$6.00 ➝ $1.50High
1/25/2019WedbushSet Price TargetHold$2.00Low
11/13/2018WedbushSet Price TargetHold$2.00Medium
11/6/2018Needham & Company LLCReiterated RatingHoldHigh
10/9/2018WedbushReiterated RatingHold$2.00High
8/10/2018Needham & Company LLCReiterated RatingHoldHigh
8/10/2018WedbushReiterated RatingHold$1.00Medium
7/10/2018SVB LeerinkDowngradeOutperform ➝ Market PerformLow
7/10/2018WedbushDowngradeOutperform ➝ Neutral$6.00High
7/6/2018B. RileyLower Price TargetNeutral ➝ Neutral$1.00 ➝ $0.50High
7/6/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$1.50 ➝ $1.00Medium
5/17/2018WedbushReiterated RatingOutperform$3.00Low
3/28/2018B. RileyInitiated CoverageNeutral$1.00High
3/8/2018BMO Capital MarketsSet Price TargetMarket Perform ➝ Hold$1.00High
1/16/2018Chardan CapitalReiterated RatingNeutralLow
1/5/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$2.00High
12/11/2017WedbushReiterated RatingOutperform$4.00High
11/14/2017Needham & Company LLCReiterated RatingHoldN/A
8/7/2017WedbushReiterated RatingOurperform$4.00Medium
8/2/2017Needham & Company LLCReiterated RatingHoldHigh
8/2/2017Chardan CapitalDowngradeBuy ➝ NeutralLow
6/13/2017WedbushReiterated RatingOurperform$6.00Medium
6/13/2017Chardan CapitalLower Price TargetBuy ➝ Buy$5.00 ➝ $2.50Medium
6/12/2017BMO Capital MarketsSet Price TargetHold$1.00Low
5/15/2017BMO Capital MarketsReiterated RatingHoldLow
3/29/2017WedbushReiterated RatingOutperform$6.00Low
3/6/2017WedbushLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.00N/A
3/3/2017CowenReiterated RatingHoldN/A
3/3/2017Cantor FitzgeraldLower Price TargetBuy$7.00 ➝ $4.00N/A
2/8/2017WedbushReiterated RatingOutperform$8.00N/A
1/30/2017WedbushReiterated RatingOutperform$8.00 ➝ $13.00N/A
1/30/2017WedbushLower Price TargetHold$13.00 ➝ $8.00N/A
1/30/2017Needham & Company LLCDowngradeBuy ➝ HoldN/A
1/30/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
1/5/2017WedbushReiterated RatingOutperform$13.00N/A
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$11.00N/A
12/7/2016Chardan CapitalLower Price TargetBuy$12.00 ➝ $5.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/27/2021

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Regulus Therapeutics logo
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.41
Low: $0.38
High: $0.42

50 Day Range

MA: $0.55
Low: $0.36
High: $0.79

52 Week Range

Now: $0.41
Low: $0.34
High: $2.32

Volume

1,407,367 shs

Average Volume

2,541,131 shs

Market Capitalization

$35.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Regulus Therapeutics?

The following equities research analysts have issued reports on Regulus Therapeutics in the last year: Cantor Fitzgerald, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for RGLS.

What is the current price target for Regulus Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Regulus Therapeutics in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 386.6%. Cantor Fitzgerald has the highest price target set, predicting RGLS will reach $2.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $2.00 for Regulus Therapeutics in the next year.
View the latest price targets for RGLS.

What is the current consensus analyst rating for Regulus Therapeutics?

Regulus Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RGLS will outperform the market and that investors should add to their positions of Regulus Therapeutics.
View the latest ratings for RGLS.

What other companies compete with Regulus Therapeutics?

How do I contact Regulus Therapeutics' investor relations team?

Regulus Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (858) 202-6300 and its investor relations email address is [email protected] The official website for Regulus Therapeutics is www.regulusrx.com.